Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | TOP2A | P11388 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ALPG | P10696 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20162277 | 0.88 | MAPT (0.47) | MAPTLMNASMN1; SMN2HPGDKDM4E | |
| SCHEMBL23407471 | 0.88 | MEN1 (0.57) | MAPTLMNASMN1; SMN2HPGDTOP2A | |
| SCHEMBL20162278 | 0.84 | KDM4E (0.46) | MAPTLMNASMN1; SMN2HPGDTOP2A | |
| SCHEMBL20162241 | 0.84 | TOP2A (0.62) | MAPTLMNASMN1; SMN2TOP2AALDH1A1 | |
| SCHEMBL23407459 | 0.84 | ALOX5 (0.47) | MAPTLMNASMN1; SMN2HPGDTOP2A | |
| SCHEMBL23407473 | 0.84 | KDM4E (0.41) | MAPTLMNASMN1; SMN2HPGDTOP2A | |
| SCHEMBL20162247 | 0.84 | PTP4A3 (0.43) | MAPTLMNASMN1; SMN2HPGDTOP2A | |
| SCHEMBL20395525 | 0.83 | MAPT (0.58) | MAPTLMNAHPGDKMT2A | |
| SCHEMBL23407462 | 0.81 | ESR1 (0.43) | MAPTLMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL23407472 | 0.80 | ESR1 (0.44) | MAPTLMNAKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210161783-A1 | USE OF SPECIFIC BENZYLIDENE MALONATES FOR PROTECTING THE SKIN FROM CHEMICALLY INDUCED STRESS | MERCK PATENT GMBH (DE) | 2021-06-03 | — | — | US | disclosed |
| US-20180207080-A1 | COMPOSITIONS OF FLUORINATED SURFACTANTS AND ANTIOXIDANTS | MERCK PATENT GMBH (DE) | 2018-07-26 | — | — | US | disclosed |
| EP-3322400-A1 | COMPOSITIONS OF FLUORINATED SURFACTANTS AND ANTIOXIDANTS | Merck Patent GmbH (DE) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207080-A1 | COMPOSITIONS OF FLUORINATED SURFACTANTS AND ANTIOXIDANTS | LPO, CAT, GPX4 | MAPT 1864/4885LMNA 2333/4885SMN1; SMN2 1302/4885 |
| US-20210161783-A1 | USE OF SPECIFIC BENZYLIDENE MALONATES FOR PROTECTING THE SKIN FROM CHEMICALLY INDUCED STRESS | MAL2, GAA, ME2 | MAPT 2297/4885LMNA 2640/4885SMN1; SMN2 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.